Goldman SachsvsHealth In Tech

GS and HIT stock compared: price, dividend, valuation and results, from SEC filings.

GS

The Goldman Sachs Group, Inc.

$891.54

Value $265B

+0.32%
GS's page

Goldman Sachs (GS) has a market value of $265B and Health In Tech (HIT) $18M. Over the last year, with dividends, GS moved +11.4% and HIT -78.4%. Dividend yield: GS 2.02%, HIT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GS$265B

    HIT$18M

    GS is 14,365 times HIT

  • Revenue, 12 months

    GS$69.7B

    HIT$31M

    GS is 2,254 times HIT

  • Net income, 12 months

    GS$22.2B

    HIT-$11M

  • Operating margin

    GS–

    HIT–

  • ROIC

    GS11.3%

    HIT-67.4%

    78.7 points apart

  • P/E

    GS12.4

    HIT–

  • Dividend yield

    GS2.0%

    HIT0.0%

    2.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GS+11.4%

HIT-78.4%

50100DecFebAprJunAugOct
Returns by period
PeriodGSWith dividendsHITWith dividends
1 year since November 12, 2025+11.4%Price +9.2%-78.4%Price -78.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GSGoldman SachsHITHealth In Tech

Valuation

GSHIT
Valuation
Price$891.54$0.33
Market value$265B$18M
Enterprise value (EV)–$15M
P/E12.4–
P/E, 5-year median14.1–
P/B2.41.4
EV/EBIT––
Free cash flow yield––

Results and growth

GSHIT
Results and growth
Revenue, 12 months$69.7B$31M
Net income, 12 months$22.2B-$11M
Free cash flow, 12 months––
Earnings per share, 12 months$69.53-$0.19
Revenue growth, year on year8.9%71.0%
Revenue growth a year, past+5.5%over 5 years+31.9%over 2 years
EPS growth a year, past+15.7%over 5 years+100.0%over 1 years

Margins and returns on capital

GSHIT
Margins and returns on capital
Gross margin–50.5%
Operating margin––
Net margin31.8%-37.1%
ROIC11.3%-67.4%
ROE17.9%-64.9%

Balance sheet

GSHIT
Balance sheet
Cash$455B$10M
Total debt$389B$6.7M
Net debt / EBITDA––
Interest cover––

Dividends and buybacks

GSHIT
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$18.00–
Dividend growth a year, past+22.9%over 5 years–
Buyback yield4.7%–
Shareholder yield6.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GS or HIT

Didn't find what you were looking for?

Ask us
Which is bigger, Goldman Sachs or Health In Tech?

By market value, Goldman Sachs ($265B) is about 14,365.1 times Health In Tech ($18M), at today's prices.

How did GS and HIT stock do over the last 1 years?

Since November 12, 2025, GS's price moved +9.2% and HIT's -78.4%. With dividends: GS +11.4% (+11.4% a year), HIT -78.4% (-78.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, GS or HIT?

The dividend yield at today's price is 2.02% for Goldman Sachs and none for Health In Tech. Over the last twelve months they paid $18.00 and – per share.

Which has the higher profit margins, Goldman Sachs or Health In Tech?

Over the last twelve months, the net margin was 31.8% for Goldman Sachs and -37.1% for Health In Tech, and the operating margin – and –. Revenue was $69.7B and $31M.

Which is the better investment, Goldman Sachs or Health In Tech?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.